1. Home
  2. PEN vs ALGN Comparison

PEN vs ALGN Comparison

Compare PEN & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Penumbra Inc.

PEN

Penumbra Inc.

HOLD

Current Price

$359.68

Market Cap

12.2B

Sector

Health Care

ML Signal

HOLD

Logo Align Technology Inc.

ALGN

Align Technology Inc.

HOLD

Current Price

$164.77

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEN
ALGN
Founded
2004
1997
Country
United States
United States
Employees
N/A
21065
Industry
Medical/Dental Instruments
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.2B
12.0B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PEN
ALGN
Price
$359.68
$164.77
Analyst Decision
Buy
Buy
Analyst Count
18
11
Target Price
$350.94
$174.00
AVG Volume (30 Days)
1.5M
818.2K
Earning Date
02-17-2026
02-04-2026
Dividend Yield
N/A
N/A
EPS Growth
367.34
N/A
EPS
4.14
5.16
Revenue
$1,333,798,000.00
$3,982,622,000.00
Revenue This Year
$17.03
$2.58
Revenue Next Year
$14.38
$3.66
P/E Ratio
$86.85
$32.36
Revenue Growth
14.61
0.56
52 Week Low
$221.26
$122.00
52 Week High
$362.41
$234.19

Technical Indicators

Market Signals
Indicator
PEN
ALGN
Relative Strength Index (RSI) 73.09 51.03
Support Level $358.36 $164.44
Resistance Level $361.55 $172.36
Average True Range (ATR) 8.11 4.19
MACD 2.17 -1.00
Stochastic Oscillator 96.63 13.96

Price Performance

Historical Comparison
PEN
ALGN

About PEN Penumbra Inc.

Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.

About ALGN Align Technology Inc.

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Share on Social Networks: